Summary Three human breast cancer cell lines ZR-75-1, MDA-MB-436 and MCF-7 were found to contain respectively, 3.06, 2.69 and 1.86fmol of somatostatin-like immunoreactivity (SLI) per 106 cells. Since SLI is undetectable in the passaging media it must, therefore, be synthesised by the cells. In the presence of fetal calf serum the cells were growth inhibited by addition of somatostatin or its long-lasting analogue, Sandostatin, but only after 3 days of continuous exposure. A 1-day exposure to either peptide had little or no effect on subsequent cell growth in peptide-free medium. Inhibition of cell proliferation is not due to cytotoxic effects of the dose used (500ngml-1, each) since both peptides caused short-term stimulation of growth in the absence of serum.
Somatostatin is a neuroendocrine hormone which inhibits not only exocrine and endocrine secretion, but also mitogenesis. Somatostatin-synthesising cells have a widespread anatomical distribution, being found in regions of the central nervous system and gastrointestinal tract. In the rat somatostatin-like immunoreactivity (SLI) is particularly concentrated in the hypothalamus, pancreas and pyloric antrum but is undetectable in lung, liver, kidney, adrenal, submandibular glands or celiac plexus (Patel & Reichlin, 1978) . The results for mammary glands were not reported.
There have been few studies of the presence of SLI in breast cancer specimens. A survey of the relevant literature shows the incidence of somatostatin synthesis to be uncommon: six out of 74 cases (Nesland et al., 1985; Nesland & Holm, 1986; Spring-Mills et al., 1984; Hull & Warfel, 1987; Cross et al., 1985) . No information is available regarding SLI in normal breast, but SLI was absent in four benign mammary displasias (Spring-Mills et al., 1984) . The presence of somatostatin receptors is also an uncommon feature of breast cancer: three out of 39 cases (Reubi et al., 1987) .
Anti-tumour effects of long-lasting peptide analogues of somatostatin (such as SMS 201-995, 'Sandostatin') have been achieved clinically in hypersecretory neuroendocrine tumours; relief of symptoms is due to inhibition of peptide secretion but arrest of tumour growth has also been noted (Anderson & Bloom, 1986) . Somatostatin and its analogues inhibit mammary tumour growth in vivo (Vuc-Pavlovic et al., 1982; Klijn et al., 1986) . Inhibition of tumour growth may be indirect, through inhibition of endocrine secretion. For example, synthetic linear somatostatin inhibits the proliferation of murine mammary aplastic carcinoma in vivo by suppression of exogenous insulin and tumour-secreted insulin-like immunoreactivity (Vuc-Pavlovic et al., 1982) . Inhibition of growth may also be direct, through interaction with receptors on the target cells. The human breast cancer cell line, MCF-7, has high affinity receptors for, and is inhibited by somatostatin analogues in vitro (Klijn et al., 1986; Setyono-Han et al., 1987) .
In this report we confirm the growth inhibitory effects of Sandostatin and somatostatin on the oestrogen receptorpositive human breast cancer cell lines, MCF-7 (SetyonoHan et al., 1987) and ZR-75-1 (Scambia et al., 1988) Radioimmunoassay of somatostatin-like material Cells (1-5 x 108) were harvested by gentle scraping from 125cm2 flasks into phosphate-buffered saline (pH 7.4). Cells were pelleted and extracted with acidified ethanol (95% in I N HCI) by repeated syringing followed by shaking for 2 h at 4°C. The extract was centrifuged at 100,OOOg, 1 h and the resulting supernatant was evaporated to dryness in a rotary evaporator. The residue was reconstituted in 1-2 ml of binding buffer (50 mM sodium phosphate buffer, pH 7.2, containing 0.3% BSA and 10mM EDTA) and pH was adjusted to neutrality, as required.
Antiserum to somatostatin-14 (Biogenesis, UK) at a final dilution of 1:2400, 1251-Tyr11somatostatin-14 (Amersham, UK) 3,000c.p.m. and unlabelled somatostatin-14 (Sigma, USA) 2-500 fmol, or cell extract were added, in triplicate, to a series of microcentrifuge tubes and made up to a final volume of 0.4 ml with binding buffer. Tubes were incubated for 20 h at 4°C. Unbound label was then removed by addition of 10mg acid-washed charcoal and 1 mg Dextran T-70 in 0.5 ml binding buffer followed by centrifugation. Bound and free label were quantified by gamma counting.
Results

Cell proliferation
In initial experiments a range of concentrations of somatostatin, 10-500ngml-1 (6x10 -9 to 3x10-7M) and Sandostatin, 10-500ngml-1 (lx 10-8 to 5x 10-7M) were tested, without medium changes, for growth inhibition of MCF-7, MDA-MB-436 and ZR-75-1 cells. Inhibition was occasionally observed with either peptide at concentrations as low as 25 ng ml-1 The inhibition at low concentrations, however, (Figure la) is the same (>3-fold on days 6 and 9) as in experiments where the somatostatin-containing medium is unchanged during the course of study (Figure lb ). In the above conditions exogenous somatostatin, as measured by RIA, is reduced to <20% (in the presence of cells and 5% FCS) or < 50% (in the presence of 5% FCS alone) after one day incubation, and is undetectable after two days in 5% FCS with or without cells. Figure lc shows the results of a one day exposure to somatostatin followed by 8 days recovery without medium changes. There is no significant difference between control or treatment cell numbers at any stage. Continuous exposure to 500 ng ml -1 Sandostatin causes inhibition of ZR-75-1 cell proliferation on day 6 to an extent similar to that of continuous exposure to somatostatin (Figure 2a) medium is much less effective in inhibiting cell proliferation than a continuous exposure (Figure 2a and b) . The growth inhibition caused by 500ngml-1 somatostatin is not due to cytotoxic effects since, while there is no significant growth of control cells in the first day after exposure (day 0 to day 1), there is stimulation of growth of treated cells, and for the next two days treated cell numbers remain higher than controls (Figure 3) The FCS batch used in these experiments was assayed both directly and as an acid-ethanol extract and in both cases SLI could not be detected. In direct assay of undiluted FCS displacement of label was observed but dilution did not parallel calibration curve; FCS extracts produced no displacement. Dilution series of extracts from the cell lines did, however, parallel the calibration curve.
The results for MDA-MB-436 cell extract are shown in Figure 5 . SLI could not be detected in conditioned media but extraction and concentration of the media may reveal low levels of secreted SLI. This possibility is being investigated.
Discussion
Continuous exposure to either single or repeated doses of 500 ng ml-1 of either somatostatin or Sandostatin in the presence of FCS produces similar inhibition (> 3-fold, day 6) of ZR-75-1 cell proliferation compared with relevant control populations (Figures I a, b and 2a) . After only one day exposure there is little or no subsequent inhibition of growth in peptide-free medium (Figures Ic and 2b) . In serum-free conditions neither peptide causes immediate cell death, making unlikely the possibility that the inhibition observed in the presence of serum is due to non-specific toxic effects of the peptides.
The growth inhibitory effect of somatostatin becomes apparent only after somatostatin drops to undetectable levels during continuous exposure experiments and significant inhibition persists up to day 9. This may be explained by presence of active degradation products which are undetec table by RIA, Sandostatin is a long-lasting analogue of somatostatin. Rat kidney homogenates, for example, degrade somatostatin to <25% of starting levels within 1 h whereas Sandostatin is virtually unaffected for up to 20h (Pless et al., 1986) . It is likely that a saturating dose of Sandostatin remains receptorbound after the drug is removed. A one day exposure to Sandostatin, however, causes much less subsequent inhibition of growth in drug-free medium than does continuous exposure during the whole experiment. This suggests that initial receptor occupancy is not sufficient to account for the inhibition seen in continuous exposure to either peptide. Setyono-Han et al. (1987) found doses of Sandostatin above 1 X 10-8 M to be decreasingly growth inhibitory. In contrast, we found concentrations above 1 X 10-8M to be increasingly growth inhibitory, which is in agreement with the findings of Scambia et al. (1988) .
Somatostatin is undetectable in the fetal calf serum used in this investigation. The cell-associated SLI must, therefore, be synthesised by the cells. The small amounts of somatostatinlike material synthesised by the cells may result in saturation of high affinity, low capacity binding sites and their downregulation. It is possible that somatostatin and Sandostatin exert growth inhibitory effects through low affinity as well as high affinity sites. Low affinity somatostatin-binding sites have been reported (Leitner et al., 1979; Arilla et al., 1984) . Preliminary results have shown that the breast cancer cells cultured in this laboratory have specific binding sites with much lower affinity for somatostatin (unpublished data) than those described by Setyono-Han et al. (1987) ; such sites would require higher concentrations of peptide to achieve an effective degree of receptor occupancy. Secretion of SLI by the cells and possible interactions of endogenous somatostatin with high affinity receptors on the cells is currently being investigated.
These differences in receptor affinity and dose response may be due to differences in culture conditions. It has been shown that the mitogenic response of MCF-7 cells to oestrogen, for example, is determined by the species, type and batch of serum used (Devleeschouwer et al., 1987) . In the investigations of Setyono-Han et al. (1987) the passaging medium contained heat-inactivated serum and insulin while the experimental medium contained heat-and charcoaltreated serum. Scambia et al. (1988) used untreated serum for passaging and charcoal-treated serum for growth experiments. Results discussed here were obtained from cells passaged and tested in untreated serum. The failure of insulin to enhance the inhibitory effects of somatostatin and Sandostatin in our experiments may also be due to differences in culture conditions.
Since SLI is rarely found in breast cancer specimens, its synthesis by the three breast cancer cell lines is surprising. This may be a result of long-term tissue culture or may indicate neuroendocrine differentiation. No studies have investigated the association of somatostatin receptor positivity with synthesis of SLI in breast cancer. The synthesis of SLI by these cells may be clinically relevant since autocrine saturation of high affinity receptors may make cells refractory to low concentrations of somatostatin. Results reported here suggest that higher doses may be effective in these circumstances.
